Status: Not yet recruiting
Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected
The purpose of this study is to evaluate the safety and immunogenicity of 426c.Mod.Core-C4b vaccine adjuvanted with 3M-052-AF + Alum in infants with perinatal HIV exposure who are without HIV at birth
Participants needed: 22
Trial details
Phase: Phase 1Age: Up to 7Biological sex: AllType: InterventionalSponsor: HIV Vaccine Trials NetworkUpdated: Sep 18, 2026Locations: 1
Eligibility criteria
Mother's age is at least 18 years and is willing and able to provide written inf... [+11]
Any World Health Organization (WHO) grade IV illness within 1 year prior to stud... [+22]